2026年全球医疗趋势率报告 全球概览和数据表 2026 Global Medical Trend Rates Report Global Overview and Data Tables

2026GlobalMedical

TrendRatesReport

GlobalOverviewandDataTables

AbouttheReport

TheAon2026GlobalMedicalTrendRatessurvey

wasconductedacross100+Aonlocationsthat

broker,administerorotherwiseadviseonemployer-sponsoredmedicalplans.Thesurveyresponses

reflectthemedicaltrendexpectationsofAon

professionalsbasedontheirinteractionswithclientsandcarriersrepresentedintheportfolioofthefirm'smedicalplanbusinessineachlocation.

Medicaltrendreferstothepredictedannual

percentageincreaseinthecostoftreatingpatients

andprovidinghealthcareservices,servingasatooltoforecastrisinghealthcareexpensesby

consideringfactorslikeinflation,serviceutilization,prescriptiondrugcosts,andadvancementsin

medicaltechnology.Itdiffersfrommedicalcost,

whichisthecurrentbaselineamount,whilemedical

trendrepresentstherateatwhichthesecostsare

expectedtogrow.

Typically,medicalcostsareassumedtoincreaseeveryyear;adecliningtrendmeanscostsare

risingmoreslowlythanbefore,notthattheyaredecreasing.Costsonlydecreasecomparedtothe

prioryearifthemedicaltrendisnegative.

Thetrendratefiguresshowninthisreportrepresent

thepercentageincreasesinmedicalplanunitcosts,bothinsuredandself-insured,thatareanticipatedforthecomingyear.Themedicaltrendrates

providedarenotmeanttorepresentanoverview

ofeachlocation'shealthcarecostsasawhole,

meaningcareshouldbetakenininterpretingthe

informationpresentedhere.

2026GlobalMedicalTrendRatesReport

ExecutiveSummary

The2026GlobalMedicalTrendRatesReportisbeingreleasedamideconomicandgeopolitical

uncertaintyincludingrecentlyannouncedglobal

tariffs.Whileglobalinflationcontinuestoshow

signsofcooling,somecountriesandregionsarestill

experiencinghigherlevelsofinflationcomparedto2025,particularlyinpartsofLatinAmerica,Africa

andtheMiddleEast.Manycountriesintheseregionsaredependentonimportsandfeeltheimpactof

inflation,currencyfluctuationsandtariffsmoreacutelythanothers.

Inadditiontomacroeconomicglobalfactors,trendsinthehealthcarespacearealsocontributingtothe

continuedhighmedicalinflationratescomparedto

historicalnorms.Theseincludehigherutilizationrates,theadoptionofnewadvancedtechnologies

andagrowingdemandforprivatehealthcare

services.Additionally,Europe,Asia-Pacific(APAC)andLatinAmericaallciteagingpopulationsas

anotherkeydriverofincreasedmedicalcosts.

Despitesustainedupwardcostpressures,theglobalaveragemedicaltrendratefor2026isexpectedtobe9.8%,continuingthetrendfromlastyearofdeclining

increasesyearoveryearandareturntoaglobalincreaserateinthesingledigitsforthefirsttimesince2023.

Inthisyear'sresults,wecontinuetoseevariation

inthemedicaltrendbothwithinandacrossregions.

Therefore,itremainsimportanttohighlightregional

trends,includingtheconditionsdrivingthetrend

rateandthewaysinwhichcompaniesaremitigating

theincreaseswithincountriesandregions.Hereare

somehighlightsacrossregions:

·Whilestillthesecondlowestgrossmedicaltrendrateacrosstheregions,NorthAmerica(comprisedofCanadaandtheUnitedStates)isoneofonlytworegionswithananticipatedgrossmedicaltrend

ratehigherthanthatpredictedfor2025,at9.3%

(up50basispoints(bps)from8.8%in2024)and

theregionwiththehighestyear-over-yearincrease.

WhilemanyfactorsdrivecostshigherinNorth

America,itisnotablethatthegrossmedicaltrend

ratemovedalmostexactlyintandemwiththe

inflationrate(whichincreased40bps).

·APACisthesecondregionwithananticipated

grossmedicaltrendratehigherthanwhatwas

predictedfor2025,at11.3%(up20bpsfrom11.1%in2024).Thisisespeciallynotableasinflationis

coolingsemi-significantlyinAPAC(decreaseof

40bpssincelastyear),sotheincreaseinthenet¹medicaltrendratesismuchhigherat60bps(8.9%

vs.8.3%).

oAroundonethirdofAPACmarkets-includingChina,Singapore,thePhilippinesandIndia-expectaslightdecreaseinmedicaltrendrates

for2025,duetomoderatedutilizationandwellbeinginitiatives.

Netindicatesmedicaltrendratesnetofdomesticgeneralinflationrates.

2026GlobalMedicalTrendRatesReport

3

4

oOffsettingandcounteractingthesedeclinesisupwardpressureintheremainingtwo-thirdsofcountries,drivenbyagingpopulations,chronicdiseaseburden,increasedhealthcareutilizationandadoptionofadvancementsintechnology.

●TheMiddleEastandAfrica(MEA)alsoseenet

medicaltrendrateshigherthanlastyear(7.6%in

2026vs.7.3%in2025),butcontrarytoAPAC,thegrossratesinMEAareprojectedtobelowerthanlastyearduetocoolinginflation(15.3%in2026vs.15.5%in2025).

oInMEA,overhalfofthemarketsareprojectinglowermedicaltrendrateincreasesin2026

thanin2025,includingSaudiArabia,oneof

MEA'slargestcountries.Meanwhile,otherlargecountriessuchasSouthAfricaandtheUnitedArabEmiratesareexpectingmedicaltrend

ratestostaythesame,whilestillotherssuch

asNigeriaareprojectingsignificantincreases.

Thevariationinthechangeinthemedicaltrend

ratesinMEAisasdiverseastheregionitself

oWhereincreasesareexpected,thereasons

mostoftencitedareincreaseddemandfor

healthcareservices,dependenceonimportscombinedwithcurrencydepreciation,and

chronicdiseaseburden.

includingthecontinuedintroductionofadvancedmedicaltechnologies,dependenceonimported

pharmaceuticalsandincreasedfrequencyandseverityofhigh-costclaims.

oTheslightdeclineobservedislargelydriven

bylowerincreasesinthemedicaltrendrate

inBrazilandColombia,twoofLAC'slarger

economies.Thisdropintrendisduelargelytochangingcarepatternsalleviatingtheupwardpressureoncostresultingfromhigh-pricedclaims(e.g.,hospitalizations).

·Europeagainbenefitedfromadecliningannual

generalinflationrate,withaprojectedmedical

trendfor2026of8.2%,downfrom8.9%in

2025.SeventypercentofthecountriessurveyedinEuropeareprojectingadecreasingorflat

medicaltrendratefor2026ascomparedto2025,

includingfourofEurope'sfivelargestcountries.

oThemostnotabledecreaseinmedicaltrend

rateisthe5%reductionintheUK,duetothe

flatteningoutofthepost-pandemicsurgein

utilization.Thisdecreaseintrendsuggeststhat

theincreasedpremiumswehavebeenseeing,whilenotexpectedtosubside,willremainmorestable.Asaresult,medicalinflationratesareexpectedtoreduceslightly.

·LatinAmericaandtheCaribbean(LAC)are

projectedtoexperienceaslightdeclineinmedicalcostgrowthwithaprojectedgrossmedicaltrendrateof10.2%for2026,down50bpscomparedtothe10.7%forecastedin

2025.However,thistrendremainselevated

comparedtohistoricalaverages.Thepersistenceofhighmedicalcostsisdrivenbyseveralfactors,

oMeanwhile,othercountriesinEuropecontinuetoprojectmodestincreases,drivenlargelyby

increasedutilizationanddemandforprivate

healthcare.Thesefactorsaretheresultof

significantlimitationsonpublichealthcare

systems,furtherexacerbatedbyagingpopulations.

2026GlobalMedicalTrendRatesReport

2026GlobalMedicalTrendRatesReport

5

Spotlight:MedicalTrendforExpatPolicies

Backdrop

AccordingtoAon's2025InternationalPeopleMobility

Report,internationalhealthinsuranceisnowthemost

prevalentbenefitprovidedtointernationalassignees,

with79%ofexpatriatesutilizingthebenefit.Giventhis,lookingatthemedicaltrendofthesepoliciesiscrucial

whentryingtomitigatetheimpactofrisingmedicalcosts.Similartomedicaltrendpatternsobservedincountriesaroundtheworld,theanticipatedmedicaltrendfor

expatriatepoliciesvariesbyregiondependingonthe

performanceoftheinsurers,thebenefitstructureof

theirpoliciesandtheiroverallapproachtothemarket.Ingeneral,weseesimilarityintheUK/U.S.policyholder

regionat11%anticipatedgrossmedicaltrendratefor

2026,whereasAPACandMiddleEasttendtotrendhigherat15%.

Therearesomenotablehigh-costcountrieswhicharekeyexpatriatedestinations,namelySwitzerland,Singapore,HongKongandtheU.S.Theselocationswillinfluencetheclaimsexperienceandpremiumsforschemes.

MarketTrends

Wecontinuetoseecompaniesfocusedoncost

containmentintheirbenefitplans.Someemployersare

exploringalternativebenefitstrategiestomanagerising

healthcarecostswhilestillsupportingemployeewellbeing.Forexample,wehaveseenorganizationspartnerwith

providerstooffervirtualservicesfortelehealth,mental

wellbeingandphysiotherapy,whichtypicallydelivercareatalowercostperunitthanin-personconsultations.Othersareexpandingaccesstodieteticservicesfocusedon

weightmanagementconsultations,alongsideconsideringincludingGLP-1medicationsintheirhealthinsurance

coverage.Employersareincreasinglybalancinginnovationwithcostmanagement,evaluatingwhetherexpanded

benefits,suchasfamily-buildingorGLP-1coverage,alignwiththeirbroaderstrategyandworkforceneeds.

6

ConditionsBehindTheTrendRate

Thetopmedicalconditionsthatareexpectedtodrivemedicalplancostsin2026areunchangedfromthosethathadthegreatestimpactonthemedicaltrendin

2025.Thisisconsistentwithprioryears.Notableforthisyear,Musculoskeletalhasenteredthetopfive,reflectingthelargeincreaseinthepercentageofthe

populationthatstruggleswiththisissue.

1.Cardiovascular

Cardiovasculardiseases,includingdisordersoftheheartandbloodvessels,remainthetopmedical

conditionanticipatedtodriveplancostsin2026.

Collectively,cardiovascularhasbeenatopcondition

ineveryregion,withthebiggestimpactonclaims

inAPAC,EuropeandLACregions.Morethan

20countriesreportedthisasthemostimpactfulcondition,includingBrazil,BelgiumandtheUnitedArabEmirates.

2.Cancer/TumorGrowth

Cominginasthesecondleadingconditionagain

thisyear,cancer/tumorgrowthisatopfivecondition

ineveryregionwith20countriesreportingitasthe

mostimpactfulcondition,includingAustralia,Chile,SingaporeandSwitzerland.Themostcommon

cancersarelung,breast,colonandrectum,andprostatecancers².

3.HighBloodPressure/Hypertension

Highbloodpressureandhypertensionareleadingriskfactorsformanyotherconditionsandare

continuouslyreportedasdrivingadverseclaims

experienceinMEAandincreasinglyinLACand

Europe.Eighteencountriesreportitasthemost

impactfulcondition,includingHungary,Nigeria,thePhilippinesandSouthAfrica.

Riskfactorscontributingtotheleadingconditions.

Asmentionedabove,hypertensionisbothaleadingconditioninandofitselfandtheleadingriskfactor

forotherconditionsbyawidemargin.

Beyondhypertension,itisnosurprisethatphysicalinactivityandpoornutritionroundoutthetop

threeriskfactorsastheseareoftenassociated

withcancer,thenumbertwomostcostlymedicalcondition.Obesitycontinuestoplayamore

prominentroleinriskfactors,risingtonumberfour.Thisisparticularlynoteworthythisyear,asmany

countriescontinuetociteprescriptiondrugsusedforweightlossasleadingfactorsintheincreaseinmedicaltrend.Itwillbeinterestingtowatchthe

trendinthecomingyearstoseehowtheincreased

utilizationofweightlossdrugsinsomemarkets

influencesobesityasariskfactorandhowbothof

thesefactorsmayinfluencethemedicaltrend.

2Source:WorldwidecancerdatalWorldCancerResearchFundInternational

Iwcrf.oral

2026GlobalMedicalTrendRatesReport

2026GlobalMedicalTrendRatesReport

7

Spotlight:TheGlobalEmergenceofGLP-1s

Backdrop

Threeconvergingglobalhealthtrendsare

intensifyingtherelevanceandcostimpactofGLP-1therapiesonemployer-sponsoredmedicalplans:

1.Diabetesisthefourthmajorconditionthatisexpectedtodrivemedicalplancostsin2026.

2.PoornutritionandObesityaretopfiveglobalriskfactors,bothofwhichcontributetodiabetesasaleadingcostcondition.

3.PrescriptionDrugsarenowthethirdcostliestelementofmedicalplancostsglobally.

GLP-1sAroundtheWorld

GLP-1sandsimilardrugsarecurrentlyavailableastreatmentinover60%ofthecountriessurveyed.Inanumberofthesecountries,thecostofthesedrugsmaybecoveredbyemployer-sponsoredmedical

plans,meaningastheuseofthesedrugsincreases,sowillmedicalcosts.

Inmanycountries,includingbutnotlimitedto

China,Greece,MalaysiaandMexico,currentmarketpracticeisforemployerstoonlycoverthecostof

thesedrugsundertheinsuranceprogramforthetreatmentofdiagnoseddiabetes/bloodsugar

maintenance;claimsforweightlossareexcluded.Thishelpstomitigate,butnotfullyeliminate,theimpactontrendofthesedrugs.However,with

diabetesrisinginprevalence,itisonlyamatteroftimebeforethesecountriesaremoreaffectedtoo.

ImpactonPrivateSchemesandMedicalTrend

Numerouscountriesinregionsaroundtheworldarealreadyreportingthat,onaverage,10%ofthemedicaltrendratecanbeattributedtoGLP-1sandsimilardrugs,withthisamountashighas25%insomemarkets.

Netherlands

In2024,Dutchpublicpharmaciesprovideddiabetesmedicationto980,000people,anincreaseof5.9%

comparedto2023.Thetotalcostamountedto

€392million,ariseof15%.ThesharpincreaseincostsisduetomoreusersofSGLT2inhibitorsandGLP-1agonists.

Canada

Theintroductionofgenericsforweight-lossdrugsin2026willhelpoffsettheimpactofexpanded

coverageforthesemedications.

PuertoRico

Thereiswidespreadparticipationinspecialty

medications,particularlyinBiologic

Immunomodulatorsandantidiabetictreatments.GLP-1hasasignificantimpactontheincrease

intheoverallprescriptiondrugscost.Wesee

antidiabeticmedicationinthefirstfivepositionoftopdrugsbyexpense.

UnitedStates

Prescriptiondrugcostscontinuetoclimbduetoincreasedutilizationofhigh-costspecialtyandbrandtherapiessuchasGLP-1s.

Conclusion

WhileGLP-1srepresentaonce-in-a-generation

treatmentwithsignificantpotentialtoimprove

populationhealth,theyarenotappropriateforeveryworkforce.It'simportanttoassessaspectrumof

evidence-basedoptionstosupportsustainablelifestylechangeandlong-termhealthoutcomes.

6GlobalMedicalTrendRatesReport

8

Whatareleadingemployersdoingtomitigaterisingcosts?

AccordingtofindingsfromAon's2025GlobalBenefitsTrendsStudy,companies

arehyperfocusedoncostcontainment.GlobalBenefits(GB)professionals

overwhelminglypointtohighmedicalinflationastheprimarydriverofbenefitcosts.TheprimaryfocusofGBprofessionalshasshiftedtocostmanagementin2025,andthisistrueforallmultinationals,regardlessofregion,industryorcompanysize(70%ofcompaniessaythisistheirfirststrategicpriority),astheybracethemselvesforaperiodofeconomicuncertainty.

Tomitigaterisingcostsandtheriskstheybring,employersarefocusingprimarilyon

hardnegotiationswithinsurancecarriersandothervendors.Aboutthree-quartersof

companiesplantonegotiatewithexistingvendors,andabouttwo-thirdsplantogotoRFP.

Othercostcontainmentmeasuresbeinglookedatbymultinationalfirmsinclude:

implementingglobalandlocalwellbeinginitiatives,usingflexiblebenefits,introducingorincreasingemployeecostsharing,reducingless-valuedbenefits,changingglobalorlocalfundingapproaches,reducinghigh-costbenefitsandchangingbenefiteligibilityrules.Aswithmultinationals,localcompaniesarelookingtomitigateincreasedcostsandare

usingasimilarsetofstrategiesthatareunchangedfromlastyear.Whilethesestrategies

tocontaincostshaven'tchangedmuchyearoveryear,thenumberofcompanies

employingthesestrategieshasgoneup.

Wellbeinginitiativesareagaintheleading

costmitigationstrategy.Theseinitiativeshelptocontrolcostsinacoupleofways.First,byencouragingutilizationofpreventativecare,theycanavoidmoreexpensivecaredowntheroad.Second,bykeepingemployeesengagedintheirwellbeing,theycanreducethestressthatcanexacerbateotherhealthconditions.Eighty-sixpercentofcountriesreportthisasthemostprevalentcostmitigationmeasure.Cost-containmentmeasuresareaimedat

reducingorcontrollingoveruse,suchas

raisingdeductibles,copaysandtheuseof

referrals.Theyareexpectedtocontinue

toplayanimportantrolein2026.More

significantplandesignchanges—such

astheuseofflexiblebenefitplanstocap

overallbenefitcostsandaccessanddeliveryrestrictions—areallmeasuresdesignedto

incentivizeplanmemberstoseekcareinacost-effectivemannerandarealsoexpectedtocontinuetoplayarolein2026.

Flexiblebenefitplansareincreasinglyusedtomitigatemedicalcostsatagloballevel,with

twothirdsofcountriessurveyedexpecting

tousethisinitiativein2026.Flexiblebenefitplansarenowthethirdmostprevalentcost

mitigationmechanismglobally(upfrom

numberfourlastyear).Thisshiftisdriven

byanalmost10%increaseinprevalence

year-over-yearinAPAC.Apartfromallowing

employersagreaterdealofcostcontrol,

flexiblebenefitplansoftenserveasanenablerofchangeinemployees’behavior.Theseplansalsoworkasatooltodeliverdifferentiated

benefitpackagesthatcanattractandretaintalent,whilealsoofferingadaptivebenefitstomeetindividualneeds.

2026GlobalMedicalTrendRatesReport

“

Asemployer-sponsoredmedicalplanscontinuetorepresentasignificantportionofoverallrewardsinvestment,theneedforeffectivecostmanagementhasneverbeengreater.Wetrustthattheinsightsanddataprovidedinthisreportwillsupportyourorganizationas

youevaluateandrefineyourbenefitsprogramsfor2026andbeyond.IfyouwouldliketodiscusshowAon’sexpertisecanhelpyounavigatethesechallengesandoptimizeyourbenefitsstrategy,pleaseconnectwithyourAonadvisororreachouttousdirectly.

9

Aonisinthebusinessofbetterdecisions.

KathrynDavis

VicePresident,GlobalBenefits

2026GlobalMedicalTrendRatesReport

AverageMedicalTrendRates

Global/Region(Averagepercentage):

2025

2026

AnnualGeneralInflationRate

AnnualMedicalTrendRates

AnnualGeneralInflationRate

AnnualMedicalTrendRates

Gross

Net

Gross

Net

Global

2.8

10.0

7.2

2.7

9.8

7.1

NorthAmerica

2.0

8.8

6.8

2.4

9.3

6.9

Asia-Pacific

2.8

11.1

8.3

2.4

11.3

8.9

Europe

2.2

8.9

6.7

2.1

8.2

6.1

LatinAmerica&Caribbean

3.0

10.7

7.7

3.3

10.3

7.0

MiddleEast&Africa

8.2

15.5

7.3

7.7

15.3

7.6

Expat–US/UK

n/a

n/a

n/a

n/a

11.0

n/a

Expat–APAC/ME

n/a

n/a

n/a

n/a

15.0

n/a

Source:Aon

●"AnnualGeneralInflationRate"for2026isthe2026projecteddomesticgeneralinflationpublishedbytheInternational

MonetaryFund(IMF)WorldEconomicOutlookDatabase,April2025.

●AllinformationwithinthisdocumentisreportedasofOctober2025,withthe2025individualcountryfiguresasreportedin

the2025GlobalMedicalTrendRatesreport,with2025GeneralInflationfiguresbeingtheIMFoutlookreleasedinApril2024.

Downloadpreviousversionsofthisreportonourwebsite.

10

●TheIMFoutlooksareconsideredthebestavailableproxyfordomesticinflationandwereusedacrossallcountriesexceptforArgentinawhereREM(Relevamientodeexpectativasdelmercado)isthesourceused,andBermuda,wherethebest

availableproxywasthemostrecentdomesticretailinflationasreportedbytheBermudacentralbank.

●“Net”indicatesmedicaltrendratesnetofdomesticgeneral

inflationrates.ThisreportwasdevelopedinQ32025,andall

commentaryisbasedonthefiguresandpredictionsavailableatthistime.

●Theglobalaveragesdonotincludetheforecastedtrendratesforexpatpolicies–newlyaddedfor2026.

●The2026medicaltrendratefortheUnitedStateswasobtainedfromAon’sHealthValueInitiativedatabase,asapplicabletoPPOplans,adjustedtoreflectexpectedincreasespriortoanyplan,

programorcarrierchangesforcostcontainment.

●ForArgentina,Lebanon,TurkeyandVenezuela,wehave

excludedtheir2026medicaltrendratesfromregionaland

globalaveragesduetohistoricalandprevailinghyperinflationenvironments.

●Algeria,Bolivia,Botswana,DemocraticRepublicoftheCongo,DominicanRepublic,Egypt,Mongolia,Morocco,Namibia,

Senegal,SultanateofOman,SwazilandandUgandawereincludedinthetablesbelowbutwithnomedicaltrendratebeingreported.

●RussiahasbeenremovedfromtheEuropetablebelowasAonisnolongerprovidingservicesinRussia.

●An"n/a"representsratesthatwerenotmadeavailableorwerenotreportedbytherespectivesources.

2026GlobalMedicalTrendRatesReport

11

Regional/Country(Averagepercentage):

2025

2026

AnnualGeneralInflationRate

AnnualMedicalTrendRates

AnnualGeneralInflationRate

AnnualMedicalTrendRates

Gross

Net

Gross

Net

NorthAmerica

2.0

8.8

6.8

2.4

9.3

6.9

Canada

1.9

7.4

5.5

2.1

8.3

6.2

UnitedStates

2.0

9.0

7.0

2.5

9.5

7.0

Source:Aon

2025

2026

AnnualGeneralInflationRate

AnnualMedicalTrendRates

AnnualGeneralInflationRate

AnnualMedicalTrendRates

Gross

Net

Gross

Net

Asia-Pacific

2.8

11.1

8.3

2.4

11.3

8.9

Australia

3.0

5.1

2.1

3.5

5.2

1.7

Bangladesh

6.1

10.0

3.9

5.2

10.0

4.8

China

2.0

8.0

6.0

0.6

7.8

7.2

HongKong

2.3

8.0

5.7

2.2

9.0

6.8

India

4.2

13.0

8.8

4.1

11.5

7.4

Indonesia

2.6

16.2

13.6

2.5

16.9

14.4

Japan

2.1

0.9

(1.2)

1.7

2.7

1.0

Kazakhstan

7.0

29.0

22.0

9.4

29.0

19.6

Malaysia

2.5

15.0

12.5

2.2

16.0

13.8

Mongolia

10.0

n/a

n/a

9.1

n/a

n/a

NewZealand

2.5

17.0

14.5

2.0

18.0

16.0

Pakistan

12.7

n/a

n/a

7.7

23.5

15.8

PapuaNewGuinea

4.8

12.0

7.2

4.6

15.0

10.4

Philippines

3.0

15.0

12.0

2.9

14.0

11.1

Singapore

2.5

14.0

11.5

1.5

13.0

11.5

SouthKorea

2.0

10.0

8.0

1.8

11.5

9.7

SriLanka

n/a

n/a

n/a

n/a

6.5

n/a

Taiwan

1.6

n/a

n/a

1.6

8.0

6.4

Thailand

1.2

14.3

13.1

0.9

14.8

13.9

Vietnam

3.4

12.9

9.5

2.5

12.2

9.7

Source:Aon

2026GlobalMedicalTrendRatesReport

12

2025

2026

AnnualGeneralInflationRate

AnnualMedicalTrendRates

AnnualGeneralInflationRate

AnnualMedicalTrendRates

Gross

Net

Gross

Net

Europe

2.2

8.9

6.7

2.0

8.2

6.2

Austria

2.8

3.0

0.2

1.7

2.5

0.8

Belgium

2.0

13.4

11.4

2.1

11.9

9.8

Bulgaria

2.7

23.0

20.3

2.3

21.0

18.7

Croatia

2.2

10.0

7.8

2.6

10.0

7.4

Cyprus

2.0

8.0

6.0

2.0

8.0

6.0

CzechRepublic

2.0

2.0

0.0

2.0

3.7

1.7

Denmark

2.0

4.0

2.0

2.1

5.0

2.9

Estonia

2.5

20.0

17.5

3.9

20.0

16.1

Finland

1.9

5.0

3.1

2.0

5.0

3.0

France

1.8

4.5

2.7

1.6

4.5

2.9

Germany

2.0

7.8

5.8

1.9

7.2

5.3

Greece

2.1

10.0

7.9

2.1

8.0

5.9

Hungary

3.5

13.0

9.5

3.6

10.0

6.4

Ireland

2.0

12.0

10.0

1.7

10.0

8.3

Italy

2.0

6.0

4.0

2.0

7.0

5.0

Latvia

3.6

30.0

26.4

2.4

20.0

17.6

Lithuania

2.3

17.5

15.2

2.8

11.0

8.2

Luxembourg

3.1

6.5

3.4

2.1

6.0

3.9

Norway

2.6

8.0

5.4

2.2

8.0

5.8

Poland

5.0

10.0

5.0

3.4

10.0

6.6

Portugal

2.0

10.0

8.0

2.1

10.0

7.9

Romania

4.0

20.0

16.0

3.1

15.0

11.9

Serbia

3.1

20.0

16.9

3.3

15.0

11.7

Slovakia

3.9

2.1

(1.8)

2.9

3.0

0.1

Slovenia

2.0

3.7

1.7

2.3

4.3

2.0

Spain

2.4

8.0

5.6

2.0

10.0

8.0

Sweden

2.0

5.0

3.0

2.0

13.0

11.0

Switzerland

1.2

6.0

4.8

0.5

5.0

4.5

TheNetherlands

2.1

4.6

2.5

2.3

5.6

3.3

Turkey

38.4

75.0

36.6

22.8

45.0

22.2

Ukraine

7.6

19.0

11.4

7.7

24.0

16.3

UnitedKingdom

2.0

17.0

15.0

2.2

12.0

9.8

Source:Aon

2026GlobalMedicalTrendRatesReport

13

2025

2026

AnnualGeneralInflationRate

AnnualMedicalTrendRates

AnnualGeneralInflationRate

AnnualMedicalTrendRates

Gross

Net

Gross

Net

LatinAmerica&Caribbean

3.0

10.7

7.7

3.3

10.3

7.0

Argentina

59.6

61.0

1.4

17.8

21.0

3.2

Bahamas

2.2

12.0

9.8

1.3

12.0

10.7

Barbados

2.8

10.0

7.2

2.4

8.0

5.6

Bermuda

1.9

11.3

9.4

2.0

10.5

8.5

Bolivia

4.2

10.0

5.8

15.8

n/a

n/a

Brazil

3.0

12.9

9.9

4.3

9.7

5.4

Chile

3.0

7.5

4.5

3.2

7.5

4.3

Colombia

3.6

6.8

3.2

3.1

9.4

6.3

CostaRica

2.9

12.0

9.1

3.0

10.0

7.0

DominicanRepublic

4.0

5.4

1.4

4.0

n/a

n/a

Ecuador

1.5

12.4

10.9

1.5

11.6

10.1

ElSalvador

1.7

20.0

18.3

1.8

15.0

13.2

Grenada

2.0

2.0

0.0

2.0

2.0

0.0

Guatemala

4.0

12.4

8.4

4.3

13.4

9.1

Honduras

4.1

13.0

8.9

4.2

16.2

12.0

Jamaica

5.0

9.9

4.9

5.0

10.0

5.0

Mexico

3.3

14.5

11.2

3.2

14.8

11.6

Nicaragua

4.0

8.0

4.0

4.0

10.4

6.4

Panama

2.0

2.0

0.0

2.0

10.0

8.0

Paraguay

4.0

6.0

2.0

3.6

6.5

2.9

Peru

2.0

3.6

1.6

1.9

7.2

5.3

PuertoRico

2.3

4.8

2.